Sironax will present three posters at Neuroscience 2026 on SIR2501, an allosteric SARM1 inhibitor holding FDA Fast Track designation for chemotherapy-induced peripheral neuropathy, with Phase 1b/2 trials underway in ALS and CIPN. The company reports favorable safety and early biological activity, though no patient numbers, doses or effect sizes have been disclosed. SARM1 drives axonal degeneration through NAD+ depletion, placing nerve-fiber preservation within the same metabolic territory as mainstream aging research.
Key Points
- Allosteric SARM1 inhibitor aims to halt axon degeneration without active-site toxicity
- FDA Fast Track granted for chemotherapy-induced peripheral neuropathy; ALS trials ongoing
- No patient counts, doses or quantified outcomes released with poster abstracts
Longevity Analysis
Peripheral nerve integrity governs balance, grip and fine motor control — functional capacities that often fail before any major organ does, and whose loss ends independence early. SARM1 sits at the intersection of axonal survival and NAD+ metabolism, meaning the enzyme that destroys nerve fibers does so by consuming the same cofactor central to cellular energy production and repair. Preserving the conduction pathways that carry signals between brain and body is as consequential to healthspan as cardiovascular or metabolic maintenance, yet is rarely treated with comparable seriousness.
Original published by Longevity.Technology, by Kyle Umipig.